# Prasugrel

Drug · id `cardio:prasugrel` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Effient

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

Prasugrel, sold as Effient, is an antiplatelet medicine of the P2Y12 inhibitor class. The US label read lists one use: lowering the rate of thrombotic cardiovascular events, including stent thrombosis, in people with acute coronary syndrome who are to be managed with percutaneous coronary intervention (PCI). That covers unstable angina or non-ST-elevation heart attack, and ST-elevation heart attack managed with primary or delayed PCI. The label carries a boxed warning that the medicine can cause significant, sometimes fatal, bleeding.

## Technical summary

RxNorm ingredient 613391. MeSH descriptor D000068799 is Prasugrel Hydrochloride, the salt, so it is a broad match; MeSH has no descriptor for prasugrel itself. UNII G89JQ59I13 is the UNII of prasugrel hydrochloride, the salt the label names, and is a broad match. The label read is the Cosette Pharmaceuticals, Inc. label for Effient, application NDA022307, effective 2022-09-07 in openFDA; a newer label may exist outside openFDA. Generic prasugrel labels were not read. This page records label indications, the first line of the boxed warning and the class only: no trial result and no dose is given.

## Claims, with the population each applies to

## Context: People for whom the US label of prasugrel (Effient) lists an indication: acute coronary syndrome managed with percutaneous coronary intervention

Recipient: Recipient not specified; Population: Patients described in the indications section of the label. The label passages read do not state an age range.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the label passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)

### The US label of Effient (prasugrel), in the Cosette Pharmaceuticals, Inc. version dated 2022-09-07 in openFDA, lists the medicine to reduce the rate of thrombotic cardiovascular events, including stent thrombosis, in patients with acute coronary syndrome who are to be managed with percutaneous coronary intervention (PCI): patients with unstable angina or non-ST-elevation myocardial infarction, and patients with ST-elevation myocardial infarction managed with primary or delayed PCI. The label carries a boxed warning that the medicine can cause significant, sometimes fatal, bleeding.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: Patients described in the indications section of the label. The label passages read do not state an age range.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the label passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)
- Limitations: This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Only the indications, the first line of the boxed warning and the mechanism sentence were read; the rest of the boxed warning, contraindications, doses, interactions and other warnings were not recorded. Labels change, and openFDA's version may be older than the current label. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-11-09
- Sources:
  1. Supports: openFDA drug label record for EFFIENT (prasugrel tablets), Cosette Pharmaceuticals, Inc. label: indications, mechanism and boxed warning (Regulator, edition The openFDA drug label record for set id 69ea2d58-5353-4222-b61f-cab976fa7e5e (manufacturer Cosette Pharmaceuticals, Inc., application NDA022307), returned on 2026-11-09. The label text is dated 2022-09-07 (effective\_time). No other openFDA record of an Effient label was returned by a brand-name search. Generic prasugrel labels were not read.) <https://api.fda.gov/drug/label.json?search=set_id:%2269ea2d58-5353-4222-b61f-cab976fa7e5e%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1 INDICATIONS AND USAGE. Retrieved 2026-11-09T13:16:10Z. Source state: Current. Version fingerprint: f8a4f19a1b4b960d4c2bea9f3fa9e117b0f10c7b0375ddaad4c490f294932a94.
     How it applies: Label passage quoted in the research quote table (LB-04).
  2. Supports: openFDA drug label record for EFFIENT (prasugrel tablets), Cosette Pharmaceuticals, Inc. label: indications, mechanism and boxed warning (Regulator, edition The openFDA drug label record for set id 69ea2d58-5353-4222-b61f-cab976fa7e5e (manufacturer Cosette Pharmaceuticals, Inc., application NDA022307), returned on 2026-11-09. The label text is dated 2022-09-07 (effective\_time). No other openFDA record of an Effient label was returned by a brand-name search. Generic prasugrel labels were not read.) <https://api.fda.gov/drug/label.json?search=set_id:%2269ea2d58-5353-4222-b61f-cab976fa7e5e%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1.1 Acute Coronary Syndrome. Retrieved 2026-11-09T13:16:10Z. Source state: Current. Version fingerprint: f8a4f19a1b4b960d4c2bea9f3fa9e117b0f10c7b0375ddaad4c490f294932a94.
     How it applies: Label passage quoted in the research quote table (LB-05).
  3. Supports: openFDA drug label record for EFFIENT (prasugrel tablets), Cosette Pharmaceuticals, Inc. label: indications, mechanism and boxed warning (Regulator, edition The openFDA drug label record for set id 69ea2d58-5353-4222-b61f-cab976fa7e5e (manufacturer Cosette Pharmaceuticals, Inc., application NDA022307), returned on 2026-11-09. The label text is dated 2022-09-07 (effective\_time). No other openFDA record of an Effient label was returned by a brand-name search. Generic prasugrel labels were not read.) <https://api.fda.gov/drug/label.json?search=set_id:%2269ea2d58-5353-4222-b61f-cab976fa7e5e%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1.1 Acute Coronary Syndrome, unstable angina or NSTEMI. Retrieved 2026-11-09T13:16:10Z. Source state: Current. Version fingerprint: f8a4f19a1b4b960d4c2bea9f3fa9e117b0f10c7b0375ddaad4c490f294932a94.
     How it applies: Label passage quoted in the research quote table (LB-06).
  4. Supports: openFDA drug label record for EFFIENT (prasugrel tablets), Cosette Pharmaceuticals, Inc. label: indications, mechanism and boxed warning (Regulator, edition The openFDA drug label record for set id 69ea2d58-5353-4222-b61f-cab976fa7e5e (manufacturer Cosette Pharmaceuticals, Inc., application NDA022307), returned on 2026-11-09. The label text is dated 2022-09-07 (effective\_time). No other openFDA record of an Effient label was returned by a brand-name search. Generic prasugrel labels were not read.) <https://api.fda.gov/drug/label.json?search=set_id:%2269ea2d58-5353-4222-b61f-cab976fa7e5e%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1.1 Acute Coronary Syndrome, STEMI. Retrieved 2026-11-09T13:16:10Z. Source state: Current. Version fingerprint: f8a4f19a1b4b960d4c2bea9f3fa9e117b0f10c7b0375ddaad4c490f294932a94.
     How it applies: Label passage quoted in the research quote table (LB-07).
  5. Supports: openFDA drug label record for EFFIENT (prasugrel tablets), Cosette Pharmaceuticals, Inc. label: indications, mechanism and boxed warning (Regulator, edition The openFDA drug label record for set id 69ea2d58-5353-4222-b61f-cab976fa7e5e (manufacturer Cosette Pharmaceuticals, Inc., application NDA022307), returned on 2026-11-09. The label text is dated 2022-09-07 (effective\_time). No other openFDA record of an Effient label was returned by a brand-name search. Generic prasugrel labels were not read.) <https://api.fda.gov/drug/label.json?search=set_id:%2269ea2d58-5353-4222-b61f-cab976fa7e5e%22&limit=1>
     Locator: results\[0\].boxed\_warning\[0\], sentence 1. Retrieved 2026-11-09T13:16:10Z. Source state: Current. Version fingerprint: f8a4f19a1b4b960d4c2bea9f3fa9e117b0f10c7b0375ddaad4c490f294932a94.
     How it applies: Label passage quoted in the research quote table (LB-08).
  6. Background: openFDA drug label record for EFFIENT (prasugrel tablets), Cosette Pharmaceuticals, Inc. label: indications, mechanism and boxed warning (Regulator, edition The openFDA drug label record for set id 69ea2d58-5353-4222-b61f-cab976fa7e5e (manufacturer Cosette Pharmaceuticals, Inc., application NDA022307), returned on 2026-11-09. The label text is dated 2022-09-07 (effective\_time). No other openFDA record of an Effient label was returned by a brand-name search. Generic prasugrel labels were not read.) <https://api.fda.gov/drug/label.json?search=set_id:%2269ea2d58-5353-4222-b61f-cab976fa7e5e%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-09T13:16:10Z. Source state: Current. Version fingerprint: f8a4f19a1b4b960d4c2bea9f3fa9e117b0f10c7b0375ddaad4c490f294932a94.
     How it applies: Effective date of the label text read, 20220907.

## Connected pages

- Prasugrel is a P2Y12 platelet inhibitor (FDA established pharmacologic class in RxClass): P2Y12 inhibitors (drug class) (`cardio:p2y12-inhibitors`)
- FDA label lists acute coronary syndrome managed with percutaneous coronary intervention as an indication: Acute coronary syndrome (`cardio:acute-coronary-syndrome`) [a claim, not a settled fact; see claim `cardio:claim-fda-prasugrel-label-indications` and its context]
- FDA label lists unstable angina managed with percutaneous coronary intervention as an indication: Unstable angina (`cardio:unstable-angina`) [a claim, not a settled fact; see claim `cardio:claim-fda-prasugrel-label-indications` and its context]
- FDA label lists non-ST-elevation myocardial infarction managed with percutaneous coronary intervention as an indication: Non-ST-elevation heart attack (NSTEMI) (`cardio:nstemi`) [a claim, not a settled fact; see claim `cardio:claim-fda-prasugrel-label-indications` and its context]
- FDA label lists ST-elevation myocardial infarction managed with primary or delayed percutaneous coronary intervention as an indication: ST-elevation heart attack (STEMI) (`cardio:stemi`) [a claim, not a settled fact; see claim `cardio:claim-fda-prasugrel-label-indications` and its context]
- Files under this front: Medicines (`cardio:front-medicines`)

## Registry records

Records a program assembled from a public registry; no person wrote or checked them. They are counted here, not listed: the JSON record of this page lists each one in its relationships.

- 1 registry product
- 27 registry trials

## Provenance

Content hash: 5950f34e37898707d193b68076622cc568f78e299a73cfb8e37f8b8013ecec24
Last substantive edit: 2026-11-09
Evidence last checked: 2026-11-09
